Published in Expert Opin Drug Saf on July 01, 2009
Preliminary Study of Dornase Alpha to Treat Chest Infections Post Lung Transplant. | NCT01952470
Lung epithelial cells are essential effectors of inducible resistance to pneumonia. Mucosal Immunol (2013) 0.91
Extracellular matrix lumican promotes bacterial phagocytosis, and Lum-/- mice show increased Pseudomonas aeruginosa lung infection severity. J Biol Chem (2012) 0.84
Pseudomonas aeruginosa ventilator-associated pneumonia management. Infect Drug Resist (2016) 0.83
Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs (2014) 0.80
Inducible epithelial resistance protects mice against leukemia-associated pneumonia. Blood (2016) 0.76
Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease. Acta Haematol (2012) 0.76
Characterization of a human powered nebulizer compressor for resource poor settings. Biomed Eng Online (2014) 0.75
Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation. Pharmacotherapy (2013) 0.75
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Recognition of microorganisms and activation of the immune response. Nature (2007) 12.99
TLR signaling. Cell Death Differ (2006) 9.24
Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature (2007) 7.34
Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol (2007) 7.23
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med (1999) 6.23
Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest (2002) 5.94
Toll-like receptor signaling pathways. Science (2003) 5.86
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med (2006) 5.74
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis (1987) 5.63
Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med (2006) 5.37
Cystic fibrosis. Lancet (2003) 5.00
Pulmonary alveolar proteinosis. N Engl J Med (2003) 4.93
Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature (2008) 4.87
Disentangling genetic variation for resistance and tolerance to infectious diseases in animals. Science (2007) 4.41
Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet (2005) 4.22
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep (2004) 3.84
Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med (1993) 3.27
Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol (2003) 3.18
Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest (2001) 3.04
Bronchiectasis. N Engl J Med (2002) 2.91
Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med (2007) 2.85
Community-acquired pneumonia. Lancet (2003) 2.80
Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med (2008) 2.65
Mucin is produced by clara cells in the proximal airways of antigen-challenged mice. Am J Respir Cell Mol Biol (2004) 2.50
The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis (1984) 2.44
Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet (1997) 2.40
MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol (2007) 2.26
Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis (2001) 2.09
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med (2008) 2.05
Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med (2004) 1.97
Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun (1999) 1.87
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol (1989) 1.82
Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med (1999) 1.81
Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med (2002) 1.80
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis (1999) 1.79
A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest (2005) 1.79
Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis (2008) 1.75
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73
Airway mucus: From production to secretion. Am J Respir Cell Mol Biol (2006) 1.73
Gentamicin and colistin in chronic purulent bronchial infections. Br Med J (1967) 1.69
Innate immunity in the lungs. Proc Am Thorac Soc (2005) 1.66
Nosocomial pneumonia: state of the science. Am J Infect Control (2006) 1.65
Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol (1996) 1.59
Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol (2002) 1.58
A Francisella mutant in lipid A carbohydrate modification elicits protective immunity. PLoS Pathog (2008) 1.58
beta-Defensin 1 contributes to pulmonary innate immunity in mice. Infect Immun (2002) 1.57
Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest (1972) 1.55
Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm (2005) 1.54
Therapeutics targeting the innate immune system. Nat Rev Immunol (2004) 1.54
Inhaled antibiotics in cystic fibrosis. Lancet (1983) 1.53
Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother (1988) 1.50
Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med (2009) 1.49
Augmented lung inflammation protects against influenza A pneumonia. PLoS One (2009) 1.47
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest (2002) 1.46
Pneumocystis cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-kappaB-dependent mechanisms. Am J Respir Cell Mol Biol (2005) 1.45
Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med (1997) 1.44
Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med (2008) 1.44
Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype. Am J Respir Cell Mol Biol (2007) 1.41
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother (2008) 1.37
Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med (2000) 1.37
Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol (2009) 1.36
Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med (1996) 1.33
Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol (2001) 1.32
Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. J Immunol (2000) 1.32
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect (2005) 1.27
Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scand J Infect Dis Suppl (1990) 1.27
Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol (1975) 1.24
Treatment of severe pseudomonas infections of the bronchi. Br Med J (1970) 1.23
Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med (1998) 1.22
Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol (1989) 1.20
Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm (1986) 1.19
Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother (2004) 1.18
Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir Res (2006) 1.18
Sverdlovsk revisited: modeling human inhalation anthrax. Proc Natl Acad Sci U S A (2006) 1.18
Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med (2007) 1.17
Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med (2000) 1.17
Restoring airway surface liquid in cystic fibrosis. N Engl J Med (2006) 1.14
Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis (2005) 1.13
Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med (1985) 1.10
Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol (2008) 1.09
Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. Am J Respir Crit Care Med (2008) 1.09
Overview: cause and prevention in biowarfare and bioterrorism. Vaccine (2002) 1.08
Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest (2005) 1.07
Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect Immun (2003) 1.07
Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res (1999) 1.06
Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med (2005) 1.05
Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med (2007) 1.05
Breakdown of pulmonary host defense in the immunocompromised host: cancer chemotherapy. Proc Am Thorac Soc (2005) 1.04
Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest (1979) 1.03
Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis (2003) 1.02
Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis (2008) 1.02
Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis (2006) 1.01
In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application. Infect Immun (2002) 1.01
Early events in innate immunity in the recognition of microbial pathogens. Expert Opin Biol Ther (2007) 1.00
Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis (2007) 1.00
The effects of nebulized recombinant interferon-gamma in asthmatic airways. J Allergy Clin Immunol (1995) 1.00
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
Airway mucus function and dysfunction. N Engl J Med (2010) 4.41
Mucin is produced by clara cells in the proximal airways of antigen-challenged mice. Am J Respir Cell Mol Biol (2004) 2.50
Synaptotagmin-2 is essential for survival and contributes to Ca2+ triggering of neurotransmitter release in central and neuromuscular synapses. J Neurosci (2006) 2.42
Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol (2007) 2.24
Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol (2006) 2.05
Regulated airway goblet cell mucin secretion. Annu Rev Physiol (2008) 1.97
Muc5ac: a critical component mediating the rejection of enteric nematodes. J Exp Med (2011) 1.88
β2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model. Am J Respir Cell Mol Biol (2012) 1.73
Airway mucus: From production to secretion. Am J Respir Cell Mol Biol (2006) 1.73
Overtreatment of enterococcal bacteriuria. Arch Intern Med (2012) 1.69
Central role of Muc5ac expression in mucous metaplasia and its regulation by conserved 5' elements. Am J Respir Cell Mol Biol (2007) 1.68
CovS simultaneously activates and inhibits the CovR-mediated repression of distinct subsets of group A Streptococcus virulence factor-encoding genes. Infect Immun (2009) 1.62
Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol (2008) 1.62
The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther (2007) 1.61
Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (2006) 1.57
Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A (2009) 1.53
Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc (2013) 1.51
Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med (2009) 1.49
Augmented lung inflammation protects against influenza A pneumonia. PLoS One (2009) 1.47
Streptococcus mitis strains causing severe clinical disease in cancer patients. Emerg Infect Dis (2014) 1.47
Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med (2008) 1.44
Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol (2008) 1.44
Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype. Am J Respir Cell Mol Biol (2007) 1.41
Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol (2009) 1.36
Inducible innate resistance of lung epithelium to infection. Annu Rev Physiol (2010) 1.34
Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem (2002) 1.33
Munc13-2-/- baseline secretion defect reveals source of oligomeric mucins in mouse airways. J Physiol (2008) 1.33
A decade of molecular pathogenomic analysis of group A Streptococcus. J Clin Invest (2009) 1.30
Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells. Cancer Res (2004) 1.29
Naturally occurring single amino acid replacements in a regulatory protein alter streptococcal gene expression and virulence in mice. J Clin Invest (2011) 1.28
Direct interaction between Rab3b and the polymeric immunoglobulin receptor controls ligand-stimulated transcytosis in epithelial cells. Dev Cell (2002) 1.22
Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J Immunol (2011) 1.16
Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer. Int J Chron Obstruct Pulmon Dis (2011) 1.11
Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect (2007) 1.10
A3 adenosine receptor signaling contributes to airway mucin secretion after allergen challenge. Am J Respir Cell Mol Biol (2006) 1.07
Exoskeletons and exhalation. N Engl J Med (2007) 1.07
Distinct single amino acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesis. PLoS Pathog (2011) 1.07
Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization. Am J Respir Cell Mol Biol (2006) 1.06
The BH3-only protein Bik/Blk/Nbk inhibits nuclear translocation of activated ERK1/2 to mediate IFNgamma-induced cell death. J Cell Biol (2008) 1.04
Small airway mucous metaplasia and inflammation in chronic obstructive pulmonary disease. COPD (2008) 1.03
Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect (2008) 1.02
Polymorphisms in regulator of protease B (RopB) alter disease phenotype and strain virulence of serotype M3 group A Streptococcus. J Infect Dis (2012) 1.02
Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One (2012) 1.00
Cre-mediated recombination in mouse Clara cells. Genesis (2008) 1.00
Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med (2002) 0.99
In vivo demonstration and quantification of intracellular Bacillus anthracis in lung epithelial cells. Infect Immun (2008) 0.99
Synaptotagmin 2 couples mucin granule exocytosis to Ca2+ signaling from endoplasmic reticulum. J Biol Chem (2009) 0.97
Inhaled innate immune ligands to prevent pneumonia. Br J Pharmacol (2011) 0.97
Assessment of intracellular mucin content in vivo. Methods Mol Biol (2012) 0.96
Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res (Phila) (2010) 0.95
Regulated mucin secretion from airway epithelial cells. Front Endocrinol (Lausanne) (2013) 0.95
Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. Carcinogenesis (2009) 0.94
Inflammatory gene polymorphisms influence risk of postoperative morbidity after lung resection. Ann Thorac Surg (2005) 0.92
Synaptotagmin-2 controls regulated exocytosis but not other secretory responses of mast cells. J Biol Chem (2009) 0.92
Toxoplasmosis myelopathy and myopathy in an AIDS patient: a case of immune reconstitution inflammatory syndrome? Neurologist (2011) 0.91
Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. Cancer (2011) 0.89
Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol Cancer (2013) 0.89
Structural mechanism of Staphylococcus aureus Hfq binding to an RNA A-tract. Nucleic Acids Res (2012) 0.88
Natural variation in the promoter of the gene encoding the Mga regulator alters host-pathogen interactions in group a Streptococcus carrier strains. Infect Immun (2013) 0.88
Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med (2010) 0.87
Allergic lung inflammation alters neither susceptibility to Streptococcus pneumoniae infection nor inducibility of innate resistance in mice. Respir Res (2009) 0.86
Molecular characterization of an invasive phenotype of group A Streptococcus arising during human infection using whole genome sequencing of multiple isolates from the same patient. J Infect Dis (2013) 0.85
Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway inflammation. Mol Cancer (2012) 0.84
Pneumocystis carinii: cell wall beta-glucan-mediated pulmonary inflammation. J Eukaryot Microbiol (2003) 0.83
Expression and transcriptional regulation of Munc18 isoforms in mast cells. Biochim Biophys Acta (2005) 0.80
Munc18b is an essential gene in mice whose expression is limiting for secretion by airway epithelial and mast cells. Biochem J (2012) 0.80
The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med (2006) 0.80
Toll-like receptor-2/6 and Toll-like receptor-9 agonists suppress viral replication but not airway hyperreactivity in guinea pigs. Am J Respir Cell Mol Biol (2013) 0.78
Helicobacter pylori bacteremia with sepsis syndrome. J Clin Microbiol (2010) 0.78
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS (2011) 0.77
Complementary anti-inflammatory effects of a β-blocker and a corticosteroid in an asthma model. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.77
Host lung gene expression patterns predict infectious etiology in a mouse model of pneumonia. Respir Res (2010) 0.77
A better crystal ball to predict lung-cancer survival? Lancet Oncol (2006) 0.76
Deletion of the gene encoding calcitonin and calcitonin gene-related peptide α does not affect the outcome of severe infection in mice. Am J Respir Cell Mol Biol (2013) 0.75
Empirical use of fluconazole in critically ill patients: good study, but what was the hold-up? Ann Intern Med (2009) 0.75
Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation. BMJ Case Rep (2011) 0.75
Infectious respiratory disease in non-HIV immunocompromised patients. Br J Hosp Med (Lond) (2014) 0.75
Evaluation of right pulmonary artery obstruction by echocardiography in a 32-year-old woman with suggested histoplasmosis. J Am Soc Echocardiogr (2005) 0.75
Non-infectious respiratory disease in non-HIV immunocompromised patients. Br J Hosp Med (Lond) (2014) 0.75